Medulloblastoma, Childhood Clinical Trial
Official title:
Multi-center Retrospective Study on Clinical Features and Molecular Subgroups of Children and Adolescents With Medulloblastoma in China
Recently, diagnosis and treatments for medulloblastoma becomes more complicated than before since the new World Health Organization (WHO) diagnosis criteria has put molecular marker onto an ever important position. Reports and studies revealed highly correlated connection between subgroups of medulloblastoma and patient outcomes. Children's Oncology Group (COG) has launched many new studies on molecular subgroups-based specific treatment trails. In China, children and adolescents with brain tumor have been treated variously for a long time in lack of standardized comprehensive treatments. Same poor situation in basic research and clinical studies makes the Chinese children with brain tumor hardly catch up with international level in molecular diagnosis and specific treatments. There are limited studies, which were conducted by immunohistochemistry for identifying medulloblastoma molecular subgroups, indicating the similar correlation of the subgroups and outcomes to world-wide reports. As the Children's Neuro-Oncology Group (CNOG) was established in China in May 2017, it makes studies from multiple centers in children's brain tumors become practical. And the availability of DNA methylation array, NanoString and other methods in medulloblastoma subgroup identification assures the quality of the method for this study.
Studies discovered that medulloblastoma is a group of tumors with different pathogenesis
through different pathways, and majorly can be divided into four molecular subgroups.
Moreover, multicenter retrospective studies from US, Canada and European Countries revealed
that the molecular subgroup of medulloblastoma becomes an independent correlated risk factor
for the patient outcomes. This finding made WHO classification of tumours of central nervous
system consider the markers in molecular pathway be an ever important indicator in the new
diagnosis criteria. In COG prospective studies for target therapies, subgroup distinguishing
becomes indispensable, and the use of immunohistochemistry combined with NanoString, DNA
methylation arrays or other molecular methods makes subgroup identification more reliable. In
China, there are limited single institutional studies, which were all conducted by
immunohistochemistry or polymerase chain reaction (PCR), on molecular sub-grouping of
medulloblastoma, especially in pediatric patients. This multicenter retrospective study
enrolls children and adolescents (0-18y/o) with primary medulloblastoma from CNOG member
institutions across the country, with available paraffin embedded samples and reliable
follow-up information, to assess the correlation of molecular subgroups of medulloblastoma
and outcomes in Chinese population.
This multicenter study recruits eligible patients from CNOG member institutions. Data
validation and verification is double conducted by each center and investigators in central
data base. Case report form (CRF) was designed by principle investigator and will be modified
in the period of uploading first 5 cases by each participated center. The estimated
enrollment is 200 cases after sample size assessment. Descriptive statistical analysis,
Two-Sample (Independent group) T-Test and one-way ANOVA will be used in epidemiological
analysis. Cox-regression / Kaplan-Meier plot will be used in survival analysis. Chi-square
test will be used to validate the test efficiency of immunohistochemistry and NanoString
methods.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04167618 -
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 | |
| Recruiting |
NCT04174820 -
Child's Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
|
||
| Completed |
NCT04860934 -
Dual Task Training On Children With Ataxia After Medulloblastoma Resection
|
N/A | |
| Suspended |
NCT03904862 -
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01697514 -
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
|
Phase 1 | |
| Recruiting |
NCT05230758 -
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
|
Phase 3 | |
| Not yet recruiting |
NCT05406947 -
Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children
|
||
| Completed |
NCT02238899 -
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
|
N/A | |
| Recruiting |
NCT05057702 -
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
|
N/A | |
| Recruiting |
NCT04185038 -
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
|
Phase 1 | |
| Completed |
NCT04528316 -
Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor
|
N/A | |
| Terminated |
NCT02624388 -
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
|
Phase 2 |